{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:27:10Z","timestamp":1787218030022,"version":"build-2736575974"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The comorbidity of chronic hepatitis B and metabolic dysfunction-associated fatty liver disease involves a bidirectional \u201cvirus\u2013metabolism\u201d interaction mechanism, presenting a clinical paradox characterized by improved virological markers alongside an increased risk of hepatocellular carcinoma. Therefore, this article aims to systematically review the interaction mechanisms and regulatory factors between the two conditions, and to propose an integrated \u201cvirus\u2013metabolism\u201d dual-axis management framework that includes metabolism-stratified antiviral therapy and synchronous metabolic intervention, so as to provide a theoretical basis for stratified management and behavioral intervention of the comorbidity.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1920121","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:07:37Z","timestamp":1787216857000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The \u201cviral\u2013metabolic\u201d interaction mechanisms and management challenges in chronic hepatitis B combined with metabolic dysfunction-associated fatty liver disease: from clinical evidence to an integrated multidisciplinary framework"],"prefix":"10.3389","volume":"17","author":[{"given":"Qianqian","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"School of Nursing, Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengde","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"School of Nursing, Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiao","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"School of Nursing, Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"School of Nursing, Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"School of Nursing, Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingdan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"School of Nursing, Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]},{"name":"Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University","place":["Zunyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/s2468-1253(22)00317-x","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jvh.13872","article-title":"Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: a systematic review and meta-analysis","volume":"30","author":"Zhou","year":"2023","journal-title":"J Viral Hepat"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13213","article-title":"Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipogenesis in HBV-related hepatocellular carcinoma","volume":"21","author":"Bai","year":"2017","journal-title":"J Cell Mol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113721","article-title":"HBx induced upregulation of FATP2 promotes the development of hepatic lipid accumulation","volume":"430","author":"Lu","year":"2023","journal-title":"Exp Cell Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.636897","article-title":"Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: a potential target of antiviral therapy for chronic hepatitis B","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Microbiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01189-0","article-title":"Impact of metabolic dysfunction-associated fatty liver disease of varying severity on antiviral treatment outcomes and clinical prognosis in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Zhu","year":"2025","journal-title":"Infect Dis Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0004","article-title":"Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis","volume":"29","author":"Wong","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0422","article-title":"Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: challenges and perspectives","volume":"29","author":"Huang","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)","volume":"26","author":"You","year":"2023","journal-title":"J Pract Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s43856-026-01383-2","article-title":"Diagnosing and defining MASLD in people living with chronic hepatitis B","volume":"6","author":"Martyn","year":"2026","journal-title":"Commun Med (Lond)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20240327-00163","article-title":"Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (2024 edition)","volume":"32","year":"2024","journal-title":"Chin J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2025.04.007","article-title":"The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease","volume":"24","author":"Li","year":"2025","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.5009\/gnl250444","article-title":"The chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease paradox: friend or foe","volume":"20","author":"Huang","year":"2026","journal-title":"Gut Liver"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.965548","article-title":"NAFLD and HBV interplay - related mechanisms underlying liver disease progression","volume":"13","author":"Tourkochristou","year":"2022","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.039","article-title":"Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma","volume":"132","author":"Kim","year":"2007","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.molimm.2019.09.006","article-title":"LncRNA H19\/microRNA-675\/PPAR\u03b1 axis regulates liver cell injury and energy metabolism remodelling induced by hepatitis B X protein via Akt\/mTOR signalling","volume":"116","author":"Liu","year":"2019","journal-title":"Mol Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf014","article-title":"Decanoylcarnitine improves liver mitochondrial dysfunction in hepatitis B virus infection by enhancing fatty acid \u03b2-oxidation","volume":"231","author":"Sun","year":"2025","journal-title":"J Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2024.105358","article-title":"Hepatitis B small surface protein hijacking Bip is initial and essential to promote lipid synthesis","volume":"311","author":"Zuo","year":"2025","journal-title":"J Proteomics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101012","article-title":"Hepatitis B surface antigen expression impairs endoplasmic reticulum stress-related autophagic flux by decreasing LAMP2","volume":"6","author":"Liang","year":"2024","journal-title":"JHEP Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00430-014-0370-1","article-title":"Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection","volume":"204","author":"Zhang","year":"2015","journal-title":"Med Microbiol Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00909-24","article-title":"Hepatitis B surface antigen impairs TLR4 signaling by upregulating A20 expression in monocytes","volume":"12","author":"Wang","year":"2024","journal-title":"Microbiol Spectr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114020","article-title":"SFAs facilitates ceramide's de novo synthesis via TLR4 and intensifies hepatocyte lipotoxicity","volume":"147","author":"Zou","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.12449\/JCH251212","article-title":"Clinical characteristics and risk factors of patients with chronic hepatitis B complicated by metabolic dysfunction-associated fatty liver disease","volume":"41","author":"Zhao","year":"2025","journal-title":"J Clin Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/13596535211067600","article-title":"Efficacy and safety analysis of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in the treatment of chronic hepatitis B","volume":"37","author":"Cheng","year":"2024","journal-title":"Infect Dis Inf"},{"key":"B26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cgh.2023.09.040","article-title":"Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion","volume":"22","author":"Huang","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12776","article-title":"Fatty acids increase hepatitis B virus X protein stabilization and HBx-induced inflammatory gene expression","volume":"281","author":"Cho","year":"2014","journal-title":"FEBS J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.05423-11","article-title":"Cholesterol depletion of hepatoma cells impairs hepatitis B virus envelopment by altering the topology of the large envelope protein","volume":"85","author":"Dorobantu","year":"2011","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10675-5","article-title":"The hepatic steatosis, steatohepatitis and metabolic dysfunction: distinct roles in hepatocellular carcinoma occurrence in chronic hepatitis B patients","volume":"18","author":"Hu","year":"2024","journal-title":"Hepatol Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.15(5)2015.27909","article-title":"Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic fatty liver disease by toll-like receptor 4-mediated innate immune response","volume":"15","author":"Zhang","year":"2015","journal-title":"Hepat Mon"},{"key":"B31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/hep.0000000000000971","article-title":"Ag-driven CD8 + T cell clonal expansion is a prominent feature of MASH in humans and mice","volume":"81","author":"Burtis","year":"2025","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32730","article-title":"Interferon-\u03b1 could induce liver steatosis to promote HBsAg loss by increasing triglyceride level","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-023-02277-8","article-title":"Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study","volume":"21","author":"Yi","year":"2024","journal-title":"Virol J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/biomedicines13051260","article-title":"Chronic inflammation and immune dysregulation in metabolic-dysfunction-associated steatotic liver disease progression: from steatosis to hepatocellular carcinoma","volume":"13","author":"Jee","year":"2025","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6507","article-title":"HBsAg\/\u03b22GPI activates the NF-\u03baB pathway via the TLR4\/MyD88\/I\u03baB\u03b1 axis in hepatocellular carcinoma","volume":"40","author":"Jing","year":"2018","journal-title":"Oncol Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/gr.279889.124","article-title":"Long-read sequencing reveals HBV integration patterns and oncogenic impact on early-onset hepatocellular carcinoma","volume":"35","author":"Wang","year":"2025","journal-title":"Genome Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4806082","article-title":"From MASLD to HCC: what's in the middle","volume":"10","author":"Provera","year":"2024","journal-title":"Heliyon"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.12122\/j.issn.1673-4254.2025.09.23","article-title":"Lipid metabolism disorders are associated with alterations in oral microbiome and metabolites in patients with hepatitis B virus and metabolic dysfunction-associated fatty liver disease comorbidity","volume":"45","author":"Zhang","year":"2025","journal-title":"J South Med Univ"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2025.01.001","article-title":"Metabolic dysfunction-associated steatotic liver disease and the cardiovascular system","volume":"35","author":"Manolis","year":"2025","journal-title":"Trends Cardiovasc Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/cells14060428","article-title":"Pathogenic mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma","volume":"14","author":"Nakamura","year":"2025","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-023-02028-5","article-title":"SCD1 inhibits HBV replication by regulating autophagy under high lipid conditions","volume":"59","author":"Du","year":"2023","journal-title":"Virus Genes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00809-4","article-title":"The role of ChREBP in carbohydrate sensing and NAFLD development","volume":"19","author":"R\u00e9gnier","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-018-1730-1","article-title":"Modulation of hepatic inflammation and energy-sensing pathways in the rat liver by high-fructose diet and chronic stress","volume":"58","author":"Veli\u010dkovi\u0107","year":"2019","journal-title":"Eur J Nutr"},{"key":"B44","doi-asserted-by":"publisher","first-page":"101888","DOI":"10.1016\/j.jhepr.2026.101888","article-title":"Global structural determinants of MASLD: development-stratified pathways linking food systems, metabolic risk, and liver outcomes","volume":"8","author":"Paik","year":"2026","journal-title":"JHEP Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.3390\/nu16234208","article-title":"Inappropriate diet exacerbates metabolic dysfunction-associated steatotic liver disease via abdominal obesity","volume":"16","author":"Xiang","year":"2024","journal-title":"Nutrients"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.4769","article-title":"Targeting MASLD and MASH in the US Hispanic\/Latino population: a review","volume":"185","author":"Cumpian","year":"2025","journal-title":"JAMA Intern Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1631975","article-title":"Ultra-processed foods and non-alcoholic fatty liver disease: an updated systematic review and dose-response meta-analysis","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Nutr"},{"key":"B48","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/nu17010143","article-title":"Dietary influences on gut microbiota and their role in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","author":"Hamamah","year":"2024","journal-title":"Nutrients"},{"key":"B49","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/medicina62040784","article-title":"Exercise as a metabolic therapy for MASLD: beyond weight loss toward sustainable exercise strategies","volume":"62","author":"Roh","year":"2026","journal-title":"Med (Kaunas)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1249\/mss.0000000000001901","article-title":"Physical activity and sedentary time: association with metabolic health and liver fat","volume":"51","author":"Bowden Davies","year":"2019","journal-title":"Med Sci Sports Exerc"},{"key":"B51","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.cgh.2025.06.014","article-title":"Risk factors of metabolic dysfunction-associated steatotic liver disease in a cohort of patients with chronic hepatitis B","volume":"24","author":"Kalafateli","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.14740\/gr2131","article-title":"A supervised, online, home-based eccentric resistance exercise program for patients with metabolic dysfunction-associated steatotic liver disease","volume":"19","author":"Deshpande","year":"2026","journal-title":"Gastroenterol Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/ijerph22111729","article-title":"Artificial light at night, sleep disruption, and liver health: Implications for MASLD pathogenesis","volume":"22","author":"Nieva-Ram\u00edrez","year":"2025","journal-title":"Int J Environ Res Public Health"},{"key":"B54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41574-022-00746-8","article-title":"The multiple roles of life stress in metabolic disorders","volume":"19","author":"Kivim\u00e4ki","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00959-4","article-title":"Food inequity and insecurity and MASLD: Burden, challenges, and interventions","volume":"21","author":"Zelber-Sagi","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e0792","DOI":"10.1097\/hc9.0000000000000792","article-title":"The impact of food insecurity on chronic liver disease: A systematic review of the literature","volume":"9","author":"Elias","year":"2025","journal-title":"Hepatol Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.011","article-title":"Association of food insecurity with MASLD prevalence and liver-related mortality","volume":"82","author":"Younossi","year":"2025","journal-title":"J Hepatol"},{"key":"B58","first-page":"4","article-title":"Scientific research report on dietary guidelines for Chinese residents (2021) officially released","year":"2021","journal-title":"Food Health"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: The need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2025.00711","article-title":"Guidelines for primary care diagnosis and management of metabolic dysfunction-associated fatty liver disease (2025 edition)","volume":"33","year":"2025","journal-title":"Chin J Hepatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-8115.2023.12.015","article-title":"Research progress on the impact of non-alcoholic fatty liver disease on hepatitis B virus infection","volume":"43","author":"Chin","year":"2023","journal-title":"J Shanghai Jiao Tong Univ (Medical Science)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12876-026-04886-3","article-title":"Effectivity and safety of TAF in CHB patients with concurrent MASLD: A real-world study","volume":"26","author":"Zhang","year":"2026","journal-title":"BMC Gastroenterol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70864","article-title":"Impact of metabolic associated steatotic liver disease on antiviral therapy outcomes on chronic hepatitis B patients receiving antiviral therapy","volume":"98","author":"Shiue","year":"2026","journal-title":"J Med Virol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (2022 version)","volume":"30","year":"2022","journal-title":"Chin J Hepatol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"17","year":"2024","journal-title":"Obesity Facts"},{"key":"B66","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/dom.70545","article-title":"Providing holistic care for patients with metabolic dysfunction-associated steatotic liver disease\/metabolic dysfunction-associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions","volume":"28","author":"Chen","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/nu16071030","article-title":"Effect of a low-calorie dietary intervention on liver health and body weight in adults with metabolic-dysfunction associated steatotic liver disease (MASLD) and overweight\/obesity: A systematic review and meta-analysis","volume":"16","author":"Dobbie","year":"2024","journal-title":"Nutrients"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s40279-023-01918-w","article-title":"Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: A position statement from Exercise and Sport Science Australia","volume":"53","author":"Keating","year":"2023","journal-title":"Sports Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jcjd.2025.10.006","article-title":"Phase 3 ESSENCE trial: Semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"20","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2174\/1573399820666230525150437","article-title":"An update on the effect of sodium glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease: A systematic review of clinical trials","volume":"20","author":"Alfayez","year":"2024","journal-title":"Curr Diabetes Rev"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0186","article-title":"Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i10.959","article-title":"Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"27","author":"Nadinskaia","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.33963\/kp.a2023.0022","article-title":"Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society","volume":"81","author":"Gorczyca-G\u0142owacka","year":"2023","journal-title":"Kardiol Pol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goae029","article-title":"Advancements in pharmacological treatment of NAFLD\/MASLD: A focus on metabolic and liver-targeted interventions","volume":"12","author":"Ciardullo","year":"2024","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"B76","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/nejmoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3422","DOI":"10.3390\/jcm14103422","article-title":"When metabolic dysfunction-associated steatotic liver disease meets viral hepatitis","volume":"14","author":"Hasanoglu","year":"2025","journal-title":"J Clin Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/17437199.2024.2413871","article-title":"Components of multiple health behaviour change interventions for patients with chronic conditions: A systematic review and meta-regression of randomized trials","volume":"19","author":"Silva","year":"2025","journal-title":"Health Psychol Rev"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.13060","article-title":"Multidisciplinary participation: The key to a cure for non-alcoholic fatty liver disease","volume":"22","author":"Zou","year":"2021","journal-title":"J Dig Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920121\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:07:41Z","timestamp":1787216861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1920121\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2026.1920121"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1920121","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1920121"}}